Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 42

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Myeloproliferative neoplasm

Not yet recruiting

Anakinra for patients with myeloproliferative neoplasms resistant to cytoreductive therapy: a study to improve treatment response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Centre Hospitalier Regional Et Universitaire De Brest

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of venetoclax plus rituximab in adult patients with relapsed chronic lymphocytic leukemia (CLL) in Poland

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Uniwersytet Medyczny W Lublinie

Plasma cell myeloma refractory+1

Not yet recruiting

Dose optimization study of ibrutinib drug combination in adult patients with haematological diseases

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Rigshospitalet

Chronic myeloid leukaemia

Not yet recruiting

Efficacy of asciminib in chronic phase chronic myeloid leukemia patients with T315I mutation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Asciminib Hydrochloride
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Acute lymphocytic leukaemia

Not yet recruiting

Long‑term safety study of S68587 (allogeneic CD19 CAR T‑cells with TRAC and CD52 disruption) in patients with advanced lymphoid leukemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Septic coagulopathy

Not yet recruiting

Efficacy of Sivelestat in Patients with Septic Coagulopathy: A Phase IIb Randomized Controlled Trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride Ph. Eur.
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Chronic granulomatous disease

Not yet recruiting

Safety and efficacy of autologous CD34+ cells transduced with a vector encoding human NCF1 in children and adults with p47‑deficient chronic granulomatous disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years

Sickle cell disease

Not yet recruiting

Methoxyflurane versus oral oxycodone hydrochloride and morphine sulfate for pain relief in sickle cell disease vaso‑occlusive crises

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methoxyflurane 99.9%
  • Sponsor:Assistance Publique Hopitaux De Paris

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Centre Hospitalier De Versailles

Chronic lymphocytic leukaemia+1

Not yet recruiting

Safety and efficacy of venetoclax, obinutuzumab and daratumumab in adult patients with relapsed chronic lymphocytic leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Uniwersytet Medyczny W Lublinie

Acute myeloid leukaemia

Not yet recruiting

Tambiciclib Added to Venetoclax and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia in Patients Who Did Not Respond After Two Treatment Cycles

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:IIS La Fe

Acute myeloid leukaemia

Not yet recruiting

Venetoclax Added to Standard Chemotherapy and Midostaurin for Patients with FLT3-Mutated Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.